＜Highly sensitive detection of EGFR mutation in NSCLC＞
岩間 映二先生、九州大学
・Kohno et al, Cancer Sci 2013: 初回診断時のdriver mutation内訳
・Yu et al, Clin Cancer Res 2014: 再生検時の耐性二次変異の内訳
・各EGFR遺伝子変異検出法の感度
Sanger sequence method: detection limit 10%
Cobas EGFR tissue test kit: detection limit 1%
digital PCR: detection limit 0.1-0.01%
Fluidigm corporation Biomarker HD system
BioRads' QX100 system
RainDrop system
・pre EGFR-TKI treatment T790M positivity (de novo T790M positivity)
Costa et al, Clin Cancer Res 2014: 65.3%( 62/95 )
Fujita et al, J Thorac Oncol 2012: 79%( 30/38 )
Iwama et al, Oncotarget 2015: 20466-20473
・Erlotinib Chmielecki et al, Science Translational Med 2011
・Liquid biopsy
Haber et al, Cancer Discovery 650-651, 2014
digital PCR, BEAMing methodなどのhighly sensitive methodが必要
Karlovich et al, Clin Cancer Res 2016: BEAMing method vs Cobas plasma test
BEAMing(liquid) vs Cobas (tissue): sensitivity 73%, specificity 50%
Cobas(liquid) vs Cobas (tissue): sensitivity 64%, specificity 98%
→BEAMing methodよりCobas plasma testの方がspecificityに優れる
